Untargeted metabolomics often results in a significant portion of unannotated metabolites, or “metabolic dark matter,” which hinders biological interpretation. A two-step analytical approach was developed to systematically prioritize and interpret unannotated metabolites using plasma LC–MS/MS data from pregnant women with obesity as a biologically relevant test dataset. The first step involved clustering 1,021 known metabolites into ten structurally coherent groups based on the Tanimoto similarity, thus defining the biologically relevant chemical space of the dataset. These metabolites were further characterized by Absorption, Distribution, Metabolism, and Excretion (ADME) profiling, protein target prediction, molecular docking and Kyoto Encyclopedia of Genes and Genomes pathway mapping analysis, to establish biological plausibility and functional perspective. Candidate structures for 1,836 unannotated features were retrieved from PubChem using molecular formula and molecular weight matching within a ±0.5 Da tolerance. This search yielded 569,115 candidate structures, of which 368,197 unique structures were retained after curation. Tanimoto coefficient filtering reduced the candidate pool to 19,868 structurally plausible candidates, and retention time-based prioritization further refined this set to 418 high confidence candidate annotations, including 83 database-supported candidates identified through HMDB and LIPID MAPS structure database cross-referencing. RT-based prioritization effectively distinguished positional isomers sharing the same molecular formula by incorporating agreement between predicted and experimentally observed retention times. This improved discrimination among structurally similar candidates, expanded metabolite annotation confidence, and provided a scalable framework for prioritizing dark matter metabolites in untargeted metabolomics. Clustered-based workflow integrating chemical similarity and retention time to prioritize and annotate unknown metabolites
D. Bhandari, H. Paz, Keith Henderson et al.· Metabolomics· 0 citations
SARS-CoV-2 main protease (MPro) is a proven target for drug discovery of small-molecule antiviral agents due to its crucial role in viral polyprotein processing, high structural conservation across numerous divergent variants, and the lack of similar human enzymes. Unlike covalent compounds, noncovalent inhibitors of MPro do not modify the enzyme's active site, and may offer improved safety profiles, greater chemical tractability, and better oral bioavailability without the need for pharmacokinetic enhancement. In this study, we designed, synthesized and characterized thirteen noncovalent nonpeptidic SARS-CoV-2 MPro inhibitors clustered into two series (KK and KB) of compounds. The inhibitors were designed based on our recently discovered Mcule-5948770040 and its analogue HL-3-68 designed through the structure–activity relationship study. To obtain atomic details of the inhibitors' binding we solved room-temperature X-ray structures of the MPro/inhibitor complexes, and to quantify their binding and antiviral properties we performed in vitro DSF and ITC measurements and TCID50 antiviral assays. In addition, a room-temperature neutron structure of the MPro/KB-5 complex allowed direct determination of hydrogen positions, mapping intermolecular interactions and directly visualizing the protonation states and hydrogen bonding. Improved binding affinities of KK-7 and KB-3 through KB-6 could be attributed to the observed nonconventional S–H⋯F hydrogen bond and an additional conventional hydrogen bond between the carboxamide moieties and Q189. Our study provides binding details for the designed compounds and demonstrates the feasibility of our joint X-ray/neutron structure-assisted drug design approach to generate more potent noncovalent nonpeptidic MPro inhibitors.
D. Bhandari, Katerina Kovalevskaya, Leighton Coates et al.· RSC Medicinal Chemistry· 0 citations